Isotopia and Cardirad Unveil Isoprotrace® in New Markets
Isotopia Molecular Imaging, in collaboration with Cardirad, is excited to announce the launch of Isoprotrace®, an innovative Gallium-68 Gozetotide preparation kit specifically designed for prostate cancer imaging. This product will now be available in select Nordic countries, particularly Sweden and Denmark.
The introduction of Isoprotrace® signifies a remarkable advancement in making precision diagnostic tools more accessible for prostate cancer treatment. This ready-to-use, multi-dose kit allows for efficient preparation of the Gallium-68 Gozetotide solution for intravenous injection. Healthcare professionals utilizing Isoprotrace® can significantly improve the detection and management of prostate cancer with precise PET imaging capabilities. It is intended for primary staging of high-risk prostate cancer patients before curative therapy, as well as for cases with suspected recurrence indicated by elevated PSA levels.
Partnership for Progress
Cardirad, recognized as a leading distributor of healthcare products within the Nordic region, will play a vital role in ensuring the availability of Isoprotrace® to medical facilities across Sweden and Denmark. "We are thrilled to partner with Isotopia to offer this groundbreaking diagnostic solution to clinicians and patients throughout the Nordic countries," stated John Storbjörk, President of Cardirad. "Isoprotrace® equips healthcare providers with essential tools that can enhance diagnostic accuracy and optimize patient care for prostate cancer therapies."
Commitment to Excellence
Tzachi Levy, the General Manager of Isotopia's aseptic plant, expressed, "The launch of Isoprotrace® in Sweden and Denmark reflects our commitment to furthering prostate cancer care on a global scale. Collaborating with Cardirad ensures that patients and clinicians in the Nordic region have access to cutting-edge diagnostic technology."
Isoprotrace® has already obtained marketing authorization and is already available in several markets including the Netherlands, UK, and Germany. The company is also planning for its further expansion into more European countries soon, showcasing Isotopia's robust supply chain and their dedication to enhancing patient access to innovative radiopharmaceutical solutions.
About Isotopia Molecular Imaging
Isotopia Molecular Imaging stands as a global leader in the development of radiopharmaceuticals, specializing in theranostic solutions that improve diagnostic accuracy alongside treatment efficacy. The company is dedicated to delivering high-quality radiopharmaceuticals to healthcare providers all around the world, underlining its commitment to patient-centered innovation.
About Cardirad Nordic
Cardirad Nordic is renowned for distributing advanced healthcare products across both the Nordic and Baltic regions. They support healthcare providers by granting access to leading medical technologies, thus enhancing patient outcomes.
Frequently Asked Questions
What is Isoprotrace®?
Isoprotrace® is a Gallium-68 Gozetotide preparation kit intended for use in prostate cancer imaging.
Where is Isoprotrace® now available?
Isoprotrace® is being launched in Sweden and Denmark, expanding its accessibility in Nordic countries.
What is the significance of this launch?
This launch represents a critical advancement in prostate cancer diagnostics, providing healthcare professionals with improved tools for detection and management.
Which companies are collaborating on this project?
Isotopia Molecular Imaging and Cardirad are the two companies partnering for this launch.
What experience does Isotopia have in radiopharmaceuticals?
Isotopia is a global leader known for their innovation in developing reliable radiopharmaceuticals for better diagnostic and treatment outcomes.
